Company intelligence / Profile preview

Diabeloop

Grenoble, Auvergne-Rhône-Alpes, Francediabeloop.com ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Diabeloop’s DBLG1 system has demonstrated significant improvements in glycemic control for people with Type 1 diabetes. Clinical trials have shown the system can improve time-in-range without serious adverse events. Over ten thousand patients are using the technology across Europe as of mid–2025. The company continues to expand its product integrations and geographic reach.

Therapeutic areas: Endocrinology
Modalities: DeviceArtificial intelligence (therapeutic AI)Software as a medical device (SaMD)Data platform (for remote monitoring)
Industry: Therapeutic Medical Devices

Partnerships

Roche Diabetes CareViCentraSOOIL Development CompanyTerumo CorporationBIOCORPEOFlow

Beyond the preview

Go deeper on Diabeloop.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabeloop.

Explore the full profile